Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells
Author: Wang, J.
Hughes, T.
Kok, C.
Saunders, V.
Frede, A.
Groot Obbink, K.
Osborn, M.
Somogyi, A.
D'Andrea, R.
White, D.
Citation: British Journal of Cancer, 2012; 106(11):1772-1778
Publisher: Nature Publishing Group
Issue Date: 2012
ISSN: 0007-0920
Statement of
J. Wang, T.P. Hughes, C.H. Kok, V.A. Saunders, A. Frede, K. Groot-Obbink, M. Osborn, A.A. Somogyi, R.J. D’Andrea and D.L. White
Abstract: BACKGROUND: The human organic cation transporter-1 (OCT-1) is the primary active protein for imatinib uptake into target BCR-ABL-positive cells. Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used by chronic myeloid leukaemia (CML) patients on imatinib to manage musculoskeletal complaints. METHODS: Here we investigated the impact of NSAIDs on functional activity of the OCT-1 (OCT-1 activity; OA) in CML cells. RESULTS: Although ten of twelve NSAIDs tested had no significant impact on OA (P>0.05), we observed increased OA (27% increase in K562; 22% increase in KU812 cells, P<0.05) and reduced IC50(imatinib) when treated with diclofenac. Co-incubation with imatinib and diclofenac resulted in a significantly lower viable cell number compared with imatinib alone. In contrast, ibuprofen led to a significant decrease in OA, an increase in IC50(imatinib) and thus reduced the cytotoxicity of imatinib. In primary CML samples, diclofenac significantly increased OA, particularly in patients with low OA (<4 ng per 200 000 cells), and significantly decreased IC50(imatinib). Ibuprofen induced significant decreases in OA in CML samples and healthy donors. CONCLUSION: On the basis of the expected impact of these two drugs on OA, ibuprofen should be avoided in combination with imatinib. Further studies are warranted regarding the potential benefit of diclofenac to improve OA in a clinical setting.
Keywords: CML; OCT-1; drug–drug interaction; NSAIDs; imatinib
Rights: © 2012 Cancer Research UK
RMID: 0020119351
DOI: 10.1038/bjc.2012.173
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_72375.pdfPublished version505.67 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.